Join us at the 2025 Cutting Edge of Transplantation (CEoT) – Transforming Tomorrow: Leading the Way in Organ Transplantation Modernization – from February 27 to March 1 in Scottsdale, AZ. Register today to be part of the future of transplantation.

For a limited time, the AST is offering an exclusive membership discount to transplant trainees. We're on a mission to help trainees boost their careers using the AST's benefits.

Through March 31, 2025, trainees can join the AST for just $60. To join with this promotion, you must qualify as a transplant trainee and be approved for membership. To receive the discount, use code TRAINEE2025.

The Fellow of the American Society of Transplantation (FAST) designation application is now open to all members who meet the eligibility criteria. Don't miss out on joining this prestigious program and be recognized for your contributions to transplantation!

On behalf of the PSECOP and WHCOP we would like to invite you to participate in a quick survey entitled, Gender Identity Knowledge Among Transplant Professionals.

The aim of the survey is to understand providers’ knowledge and experience providing care to LGBTQ+ identifying patients. Providers include all those who participate in the transplant process, including but not limited to advanced care providers (APPs), coordinators, ethicists, nurses, pharmacists, psychologists, physicians, and surgeons.

The survey has been approved by the AST Education Committee. It will take 5-10 minutes to complete.

Thank you in advance for your time and participation.

The AST Public Policy Committee is pleased to introduce the AST Public Policy Form, a survey aimed at soliciting your perspectives on legislative and regulatory issues that significantly influence both patient care and professional practice. With this new initiative, our goal is to establish a platform for our membership to actively engage with the Public Policy Committee by sharing their invaluable ideas and perspectives. We look forward to your input as we navigate the dynamics of our ever-evolving landscape of transplant care and practice.

Although recommended in International Society for Heart and Lung Transplantation (ISHLT) guidelines, transition to mammalian targets of rapamycin (mTOR) inhibitors in heart transplant recipients is not routinely performed, in part due to perceived risk of rejection. This study sought to evaluate the incidence and risk factors for biopsy-proven, clinically relevant rejection following conversion from calcineurin inhibitor (CNI) to sirolimus (SRL) immunosuppression.

Novel approaches to improve long-term outcomes in kidney transplant recipients are required. Here, we present the five-year data from a multicenter, prospective, Phase 3b trial evaluating treatment outcomes with standard (STD) or low (LOW) dose prolonged-release tacrolimus (TAC) combined with ACEi/ARB or other antihypertensive therapy (OAHT) in Canadian kidney transplant recipients.

In July 2023, the OPTN adopted MELD3.0 to address sex-based disparities in liver transplantation (LT) opportunity and waitlist mortality. No studies have proven that MELD3.0 alleviated them.

Given the risks of cardiovascular disease among pediatric kidney transplant recipients, we evaluated whether there was an association between rapid weight gain (RWG) following kidney transplantation and the development of obesity and hypertension among children enrolled in the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) registry.